This Abbott Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Portfolio Pulse from Avi Kapoor
Top Wall Street analysts initiated coverage on several companies with positive ratings. Abbott Laboratories received an Outperform rating with a $130 price target. Arcus Biosciences, Howmet Aerospace, Bicara Therapeutics, and First National Corporation also received positive ratings and price targets.
October 08, 2024 | 1:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer initiated coverage on Abbott Laboratories with an Outperform rating and a $130 price target. Shares closed at $113.36, up 0.6%.
The Outperform rating and a price target significantly above the current price suggest a positive outlook, likely boosting investor confidence and short-term stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Morgan Stanley initiated coverage on Bicara Therapeutics with an Overweight rating and a $35 price target. Shares fell 2.8% to $24.45.
Despite the share price drop, the Overweight rating and a price target significantly above the current price suggest a positive outlook, potentially reversing the short-term decline.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 100
POSITIVE IMPACT
Hovde Group initiated coverage on First National Corporation with an Outperform rating and a $22 price target. Shares rose 0.9% to $18.37.
The Outperform rating and a price target above the current price indicate a positive outlook, likely boosting investor confidence and short-term stock price.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 100
POSITIVE IMPACT
Susquehanna initiated coverage on Howmet Aerospace with a Positive rating and a $120 price target. Shares increased 0.8% to $102.83.
The Positive rating and a price target above the current price suggest a favorable outlook, likely encouraging investor interest and short-term price appreciation.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 100
POSITIVE IMPACT
Wells Fargo initiated coverage on Arcus Biosciences with an Overweight rating and a $29 price target. Shares rose 3.9% to $17.30.
The Overweight rating and a price target well above the current price indicate a positive outlook, likely leading to increased investor interest and short-term price gains.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100